Background We have previously shown that activated T-cells from systemic lupus erythematosus (SLE) patients are resistant to the apoptotic effects of galectin-1 (Gal-1), an endogenous immunoregulatory lectin. The expression of de novosynthesised, intracellular Gal-1 (icGal-1) was also deficient in SLE activated T-cells, and we have demonstrated that icGal-1 levels affect apoptosis induction by extracellular Gal-1 (ecGal-1). However, production of icGal-1 may not be the only regulatory factor in this process, since binding of ecGal-1 to T-cells and its apoptotic activity depends on the surface glycosylation of T-cells. We have hypothesised that the cell-surface glycosylation pattern, and consequently, lectin-binding ability in SLE T-cells is altered, and that the abnormal expression of glycosylation enzymes may account for these changes.
Materials and methods Lectin-binding assays were performed using a set of plant lectins and human recombinant Gal-1 on resting and activated T-cells with multi-colour flow-cytometry in 9 patients with active SLE and 15 healthy controls. mRNA levels of thirteen glycosylation enzymes involved in the development of N-glycan structures on T-cells were measured with qPCR, and were correlated with lectin binding ability.
Results As compared with the resting state, the increase in Gal-1 binding during activation was significantly lower in SLE T-cells than in controls, and the level of Gal-1 binding maximum was significantly reduced in SLE activated T-cells than in controls. Binding maximum of plant lectins that recognise high complexity N-glycans also increased less in SLE T-cells than in controls during activation. mRNA level of sialyltransferase ST3GAL6 was increased and neuraminidase Neu1 was decreased in active SLE patients as compared to controls. The ST6GAL1/NEU1 ratio in SLE patients positively correlated with the SLEDAI disease activity index.
Conclusion SLE T-cells show decreased complexity of N-glycan structures. Increased ST3GAL6 and decreased Neu1 expression result in an increased density of terminal sialic acids, and this may explain the impaired Gal-1 binding. In addition to the previously described deficiency in icGal-1 expression upon activation, our present findings of an attenuated glycan complexity and a shift toward terminal sialylation provide a further mechanism of pathological T-cell activation and regulation of T-cell viability in SLE.
Deák M, Hornung Á, Novák J, Demydenko D, Szabó E, Czibula Á, Fajka-Boja R, Kriston-Pál É, Monostori É, Kovács L. Novel role for galectin-1 in T-cells under physiological and pathological conditions. Immunobiology. 2015220(4):483–9.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.